SCA practice case · Video consultation

“For a week or two before my period I become a different person — rage, despair, I scare myself — then it lifts”

Video consultation Adult patient Typical Gender, reproductive & sexual healthMental health & addiction

The candidate brief

This is what you would read in the 3-minute window before the patient connects. Read it once, note two or three hypotheses and one thing you must not miss, then stop.

Patient
Carys Devlin · 33 years · female
Setting
Video consultation — severe cyclical mood symptoms (no examination needed).
Past history
  • Told “bad PMS” previously
Medication
  • None recorded
Allergies
Not recorded
Recent notes
Previous consultation: advised premenstrual syndrome.
Reason for contact
“My moods before my period are wrecking my life.”

Practise this case

The full case is in the Hot Seat with the Gold plan. You get a 12-minute timer, a role-player script with facts released only when asked, examiner checkpoints by the three RCGP domains, a model consultation and the guidance behind it.

What this case tests

Show the learning points (spoiler: read after you have practised)
PREMENSTRUAL DYSPHORIC DISORDER (PMDD) is the severe, functionally impairing end of premenstrual disorders: prominent affective symptoms (irritability/RAGE, low mood/DESPAIR, anxiety, mood swings, feeling out of control) ± physical symptoms occurring in the LUTEAL phase (the 1–2 weeks before menstruation), damaging relationships/work, and RESOLVING shortly after the period starts with a SYMPTOM-FREE follicular interval — the cyclical timing with a symptom-free window being the diagnostic key. Distinguish it from ordinary (milder, non-disabling) PMS and from an underlying MOOD DISORDER with premenstrual exacerbation, where symptoms PERSIST through the cycle (worse premenstrually) rather than fully resolving. Confirm with a PROSPECTIVE symptom DIARY over at least two cycles, since retrospective recall is unreliable and the diary both confirms PMDD and excludes a persistent mood disorder. Assess severity and functional impact, and explicitly screen RISK — PMDD causes genuine distress and carries a real suicide/self-harm risk in the luteal phase — while validating strongly that this is a recognised medical condition, NOT "just PMS"/"just hormones" or a character failing (the validation is itself therapeutic after dismissal). Offer evidence-based treatment per RCOG Green-top Guideline No. 48 (2016): lifestyle measures; an SSRI (effective in PMDD, given continuously OR only in the luteal phase; unlicensed for PMS in the UK, dose per BNF; screen for bipolar features first and review within 1 week if at increased suicide risk, NICE NG222); combined hormonal contraception/ovulation suppression (a new-generation combined pill, drospirenone-containing usually more effective, cyclical or continuous, after a UKMEC check); CBT; risk explored without risk labels and with a safety plan (NICE NG225); and referral to gynaecology/specialist for severe/refractory cases (GnRH analogues ± add-back, rarely surgery), tailored to her preferences and contraceptive needs. The hidden agenda is feeling she is "going mad" and previously dismissed; recognise, confirm, assess risk, validate, and treat with shared decision-making.

The guidance behind it

Similar SCA cases

Browse all 359 cases by experience group →

gpreasoning.uk is not affiliated with or endorsed by the RCGP. Our cases are original teaching material written for practice; none is an exam recall. For anything official about the SCA, check the RCGP SCA pages.